Objective We characterized associations between central nervous system (CNS) adverse events and brain neurotransmitter transporter/receptor genomics among participants randomized to efavirenz-containing regimens in AIDS Clinical Trials Group studies in the USA.
Introduction
Efavirenz is a frequently prescribed antiretroviral, with its efficacy demonstrated in multiple clinical trials [1] [2] [3] [4] [5] [6] . However, central nervous system (CNS) symptoms are common with efavirenz [7] [8] [9] . Several CYP2B6 polymorphisms predict increased plasma efavirenz exposure, including CYP2B6 516G→T (rs3745274) [10] [11] [12] [13] [14] [15] , 983T→C (rs28399499) [15] [16] [17] [18] , and 15582C→T (rs4803419) [15] . A CYP2A6 polymorphism, − 48T→G (rs28399433), also affects efavirenz pharmacokinetics [19] [20] [21] [22] when present with CYP2B6 slow metabolizer genotypes [19, 22] . These polymorphisms explain~35% of interindividual variability in plasma efavirenz exposure [15] . A possible association with efavirenz pharmacokinetics has also been reported with UGT2B7 genotype [21] , but with small effect size [22] .
Increased likelihood of efavirenz CNS symptoms has been attributed to CYP2B6 slow metabolizer genotypes [18, 23, 24] . In an initial analysis of AIDS Clinical Trials Group (ACTG) data [18] , CYP2B6 slow metabolizer genotypes were associated with adverse events in 276 White participants (P = 0.04), but not in 217 Black participants (P = 0.58). Similarly, among 563 patients who Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.pharmacogeneticsandgenomics.com.
initiated efavirenz-containing regimens at a clinic in the Southeastern USA, slow metabolizer CYP2B6 genotypes were associated with efavirenz discontinuation for CNS symptoms in 335 White patients (P = 0.001), but not in 198 Black patients (P = 0.27) [23] . Among 1833 ACTG study participants in the USA, an association between CYP2B6 genotype and suicidality was strongest among White participants, but nearly null among Black participants [24] . The reason for this apparent difference by race is not known.
Brain neurotransmitter transporters/receptors are postulated to mediate efavirenz CNS symptoms, including the norepinephrine transporter (encoded by SLC6A2), dopamine transporter (SLC6A3), progesterone PR-B (PGR), serotonin receptors 5-HT2A (HTR2A), 5-HT2B (HTR2B), 5-HT2C (HTR2C ), and 5-HT6 (HTR6), and androgen receptor (AR) (Daria Hazuda, personal communication, 1st March 2016). Lower expression levels of neurotransmitter transporter/ receptor genes in brain tissue could possibly confer increased susceptibility to efavirenz side effects. This hypothesis may be addressed indirectly using, PrediXcan, a novel computational algorithm that uses genome-wide genotype data to infer RNA expression levels for individual genes in various human organs and tissues [25] .
We examined whether predicted expression levels of selected neurotransmitter transporter/receptor genes in brain were associated with risk for CNS adverse events in participants randomized to receive efavirenz-containing regimens in ACTG studies. We also examined whether individual polymorphisms in these genes were associated with CNS adverse events with efavirenz.
Participants and methods

Study design and participants
Data were pooled from antiretroviral-naive individuals who had been randomly assigned to initiate efavirenzcontaining regimens in four studies: ACTG384 (ClinicalTrials. gov: NCT00000919) [26, 27] , A5095 (ClinicalTrials.gov: NCT00013520) [2, 28] , A5142 (NCT00050895) [3] , and A5202 (NCT00118898) [6] . Drug class components of the regimens were randomly assigned (efavirenz-based regimen vs. comparator regimen) except for nucleoside analog choice in A5142. Genetic association testing was limited to participants who consented to genetic testing under ACTG protocol A5128 [29] . Participants self-reported race/ethnicity.
Each protocol required reporting of signs, symptoms, or diagnoses at each visit, severe and life-threatening graded signs or symptoms [30] , and signs or symptoms that led to change in study regimen. Diagnoses were not graded. Further, study A5142 required report of all moderate signs or symptoms, study ACTG384 required entry of all signs and symptoms grade 3 or greater, all signs and symptoms that resulted in dose modification regardless of grade, and all grade 2 or greater CNS symptoms, and A5095 and A5202 required report of moderate CNS symptoms. Site institutional review boards approved each study, and participants provided written informed consent.
Outcomes
The outcome of interest was new onset grade 2 or greater CNS signs or symptoms that were consistent with possible efavirenz effect. These included agitation, behavior changes, abnormal cognition, confusion, depression, difficulty concentrating, dizziness, abnormal dreams, excessive anger, hyperactivity, inappropriate behavior, insomnia, lethargy, change in level of consciousness, light-headedness, memory loss, psychiatric mental status change, rage, or sleeping problems. Adverse event data were based on self-report, and did not involve questionnaires specifically targeting CNS events. Death by suicide was also considered a possible efavirenz effect.
Cases were participants with grade 2 or greater efavirenzconsistent CNS signs or symptoms, or with death due to suicide, documented within 48 weeks after study entry while still being prescribed efavirenz, or within 2 weeks after efavirenz was discontinued. Controls were participants with no documented efavirenz-consistent CNS signs or symptoms regardless of any grade after study entry while being prescribed efavirenz for at least 96 weeks. Cases and controls were excluded for any neuropsychological signs or symptoms of any grade documented at study entry.
Covariates
Baseline covariates included in multivariable models included age, sex, and CYP2B6/CYP2A6 genotype. The first two principal components generated from genome-wide genotype data were also included to minimize confounding by unrecognized population stratification. Analyses performed separately among self-identified White, Black, and Hispanic participants also adjusted for age, sex, and CYP2B6/CYP2A6 genotype, but not principal components.
Genetic assays and data
Genotypes for CYP2B6 516G→T, 983T→C, 15582C→T, and CYP2A6 − 48T→G were largely available from a MassARRAY iPLEX Gold (Sequenom Inc., San Diego, California, USA) assay, generated by Vanderbilt Technologies for Advanced Genomics [15] . Genome-wide genotype data largely available from a previous immunogenomics project [31] were generated by Illumina HumanHap 650Y array for A5095 and by Illumina 1M duo array for A5142 and A5202 (Illumina, San Diego, California, USA). Quality control and imputation of genome-wide data were performed as described elsewhere [32] . The PLINK program and R statistical programming language were used for QC procedures [33, 34] . Polymorphisms were censored for call rates of less than 99%. We excluded 18 samples where genetically inferred sex differed from clinical data, or missing sex status that could not be inferred, 105 samples with overall genotyping call rates less than 99%, and 17 samples with cryptic relatedness based on identity by descent estimates more than 0.3 from~100 000 pruned single nucleotide polymorphisms (SNPs).
Post-QC data were imputed to 1000 Genomes [35] after converting to genome build 37 using liftOver [36] and stratifying by chromosome to parallelize imputation processing. ShapeIt2 [37] was used to check strand alignment and to phase data. The IMPUTE2 algorithm [38] was used to impute additional genotypes that were available in the 1000 Genomes reference panel, but not directly genotyped. Each chromosome was segmented into 6 Mb regions with at least 3500 reference variants in each region. Imputed genotypes were included if posterior probabilities exceeded 0.9.
Quality of imputed data was assessed following the Electronic Medical Records and Genomics protocol [39] . Each chromosome from each phase was checked for 100% concordance with genotyped data. We dropped imputed SNPs with info scores of less than 0.7, genotyping call rates of less than 99% and minor allele frequencies of less than 0.01.
Twelve composite CYP2B6/CYP2A6 genotype levels that predict progressively greater plasma efavirenz exposure were defined by combinations of three CYP2B6 and one CYP2A6 polymorphisms [15, 22] as described elsewhere [22] . Each CYP2B6/CYP2A6 polymorphism (rs3745274, rs28399499, rs4803419, and rs28399433) was in Hardy-Weinberg equilibrium in White, Black, and Hispanic participants analyzed separately except rs4803419 in White participants (multiple testing-corrected P = 0.045). Consent for genetic analysis was obtained under ACTG protocol A5128 [29] , and the ACTG approved this use of DNA.
PrediXcan
PrediXcan was used to infer, from genome-wide genotype data, the heritable component of RNA expression levels in 43 available reference tissues [25] , using the 2015 PrediXcan models. PrediXcan was able to infer expression of~10 000 genes in each tissue. The 10 reference brain tissues analyzed included anterior cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens, and putamen. The additional 33 reference tissues included adipose subcutaneous, adrenal gland, aorta, coronary artery, tibial artery, breast, Epstein-Barr virus-transformed lymphocytes, transformed fibroblasts, sigmoid colon, transverse colon, gastroesophageal junction, esophagus mucosa, esophagus muscularis, heart atrial appendage, heart left ventricle, liver, lung, skeletal muscle, tibial nerve, ovary, pancreas, pituitary gland, skin suprapubic not sun exposed, skin lower leg sun exposed, terminal ileum, terminal ileum (elastic net), spleen, stomach, testis, thyroid, whole blood unscaled, whole blood, and cross tissue.
Statistical analysis
We characterized associations between predicted expression of six autosomal brain neurotransmitter transporter/receptor genes (SLC6A2, SLC6A3, PGR, HTR2A, HTR2B, HTR6) and efavirenz CNS adverse events. We also characterized associations between polymorphisms in these six genes as well as AR and HTR2C and efavirenz CNS adverse events. Because AR and HTR2C are on the X chromosome, PrediXcan cannot infer their expression. Analyses controlled for CYP2B6/CYP2A6 genotype level as a linear covariate, age, and sex. The first two principal components, calculated using EIGENSOFT [40] were used to adjust for global ancestry in analyses that pooled all race/ethnicity groups. Associations with CNS adverse events were evaluated using logistic regression models, stratified by race/ethnicity. As a positive control, associations between baseline total plasma bilirubin concentration and hepatic UGT1A1 expression were similarly evaluated, controlling for CYP2B6/CYP2A6 genotype level, age, sex, and the first two principal components. The Bonferroni method was used to adjust for multiple testing.
Results
Study participants
Of 4742 participants from ACTG studies ACTG384, A5095, A5142, and A5202, a total of 2171 who had been randomly assigned to initiate efavirenz-containing regimens consented to genetic testing at research sites in the USA. Of these participants, 1425 were successfully genotyped for CYP2B6/CYP2A6 and had imputed genome-wide genotype and principal component data. Of these participants, 820 met definitions as either cases with documented grade 2 or greater efavirenz-consistent CNS adverse events by week 48 (n = 167) or efavirenz-tolerant controls that continued efavirenz for at least 96 weeks without documented CNS adverse events (n = 653). Participant disposition is shown in Fig. 1 . Baseline characteristics of study participants are presented in Table 1 . Females were underrepresented among cases versus controls.
CYP2B6/CYP2A6 genotype and CNS adverse events
In logistical regression analyses, among the 820 participants who were evaluable as either cases who developed grade 2 or greater CNS adverse events by week 48 (n = 167), or efavirenz-tolerant controls (n = 653), and controlling for age, sex, and the first two principal components, CYP2B6/CYP2A6 genotype level was associated with grade 2 or greater CNS adverse events within 48 weeks [odds ratio (OR): 1.07; 95% confidence interval (CI): 1.00-1.15; P = 0.044]. In analyses performed separately among 335 White, 264 Black, and 184 Hispanic participants, and adjusted for age and sex but not principal components, ORs for association between CYP2B6/ CYP2A6 genotype level and grade 2 or greater CNS event by week 48 were similar to the total group (1.10 for White, 1.07 for Black, and 1.08 for Hispanic participants), but none were statically significant (P > 0.10 for each). In the above multivariable models, female sex was associated with fewer grade 2 or greater CNS adverse events within 48 weeks among all participants (OR: 0.33; 95% CI: 0.17-0.63; P = 0.001), and among White participants (OR: 0.14; 95% CI: 0.18-1.04; P = 0.055) and Black participants (OR: 0.43; 95% CI: 0.19-0.96; P = 0.040) analyzed separately.
Predicted expression levels of neurotransmitter transporter/receptor genes and CNS adverse events For each participant, genome-wide genotype data were used to predict the heritable component of gene expression for 43 tissues, including multiple reference regions of the brain. Primary analyses characterized associations between six neurotransmitter transporter/receptor genes postulated to mediate efavirenz effects in brain (SLC6A2, SLC6A3, PGR, HTR2A, HTR2B, HTR6), and grade 2 or greater CNS adverse events within 48 weeks. Among all participants, and controlling for CYP2B6/CYP2A6 genotype level, age, sex, and two principal components, the lowest nominal P value was for PGR in hippocampus (P = 0.012). The two lowest nominal P-value results for each gene and associated brain regions are presented in Table 2 . None were significant after correcting for multiple testing. In analyses performed separately among White, Black, and Hispanic participants, and adjusted for age and sex but not principal components, there were no significant associations. The lowest P value in White participants was for HTR2A in cerebellar hemisphere (P = 0.12), in Black participants was for SLC6A2 in caudate (P = 0.17), and in Hispanics participants was for HTR2A in cortex (P = 0.082). The two lowest nominal P-value results for each gene within race/ethnicity group and associated brain regions are presented in Supplementary Table 1 (Supplemental digital content 1, http://links.lww.com/NMC/A133).
Following the approach of Li et al. [41] , we were able to assess correlations between predicted and observed gene expressions in reference datasets in brain tissue for SLC6A3, HTR2B, and HTR6. Among Whites, the strongest correlations were with SLC6A3 (r 2 = 0.038) and HTR2B in hypothalamus (r 2 = 0.028). Among Africans, the strongest correlations were with SLC6A3 in hypothalamus (r 2 = 0.040) Fig. 1 Derivation of the study sample. Derivation cases who developed grade 2 or greater efavirenz-consistent central nervous system (CNS) adverse events by week 48, and efavirenz-tolerant controls who continued efavirenz for at least 96 weeks without efavirenz-consistent CNS adverse events, during participation in ACTG384, A5095, A5142, or A5202 are shown. PC, principal components. and HTR6 in cortex (r 2 = 0.029). These would not be considered well-predicted genes.
Predicted expression levels for all evaluable genes in brain and CNS adverse events
In secondary analyses, we explored associations with expression across all evaluable autosomal genes in the brain. Among all participants, and controlling for CYP2B6/CYP2A6 genotype level, age, sex, and two principal components, the lowest nominal P value was for RCE1 (a metalloproteinase) in cerebellar hemisphere (P = 5.3 × 10 − 8
). The two lowest nominal P-value results for each brain region are presented in Table 3 . In analyses performed separately among White, Black, and Hispanic participants, and adjusted for age and sex but not principal components, there were no significant associations after adjusting for multiple comparisons. The lowest P value in White participants was for ACSF3 in anterior cingulate cortex (P = 9.5 × 10
), in Black participants was for TRPC3 in cerebellar hemisphere (P = 1.9 × 10 − 5 ), and in Hispanics participants was for KLK5 in cerebellar hemisphere (P = 3.0 × 10
). The two lowest nominal P-value genes for each brain region each gene within race/ethnicity group are presented in Supplementary Table 2 (Supplemental digital content 1, http://links.lww.com/NMC/A133).
Predicted UGT1A1 expression in all tissues and baseline plasma bilirubin concentration
As a positive control we considered total plasma bilirubin concentration at baseline, which should correlate inversely with UGT1A1 expression, especially in liver. By linear regression analysis involving 1354 participants evaluable for baseline plasma bilirubin, and controlling for CYP2B6/ CYP2A6 genotype, age, sex, and two principal components, hepatic UGT1A1 expression was associated with bilirubin concentration (P = 3.4 × 10 − 27 ). This association was also present among White participants (P = 4.3 × 10 ) analyzed separately without adjusting for principal components (Table 4 ). In contrast, for 17 nonliver tissues for which PrediXcan could predict UGT1A1 expression levels, only three had nominal P values less than 0.05 for association of UGT1A1 expression with baseline total bilirubin -skeletal muscle (P = 0.002), non-sun-exposed skin (P = 0.005), and putamen (P = 0.046). P values exceeded 0.10 for the other 14 tissues. This established that PrediXcan could identify a true gene expression-phenotype association in our dataset, and could do so in a tissue-specific manner.
Neurotransmitter transporter/receptor gene polymorphisms and CNS adverse events
Primary analyses characterized associations between polymorphisms in the eight neurotransmitter transporter/ receptor genes ( 100 kB) noted above (SLC6A2, SLC6A3, NR3C3, HTR2A, HTR2B, HTR2C, HTR6, NR3C4) and grade 2 or greater CNS adverse events within 48 weeks. Analysis among all participants, and controlling for CYP2B6/CYP2A6 genotype level, age, sex, and two principal components, the lowest nominal P value was for rs12393326 in HTR2C (P = 6.7 × 10 − 4 ). The two lowest nominal P-value polymorphisms among all participants and among White, Black, and Hispanic participants analyzed separately are presented in Table 5 . None were significant after correcting for multiple testing.
Genome-wide polymorphisms and CNS adverse events
To complement the above analyses focused on eight neurotransmitter transporter/receptor gene polymorphisms, secondary analyses explored polymorphism associations genome-wide. Analysis among all participants, and controlling for CYP2B6/CYP2A6 genotype level, age, Logistic regression analysis involved 820 total participants, which included 167 grade 2 or greater CNS event cases and 653 efavirenz-tolerant controls. The analysis controlled for CYP2B6/CYP2A6 genotype level, age, sex, and the first 2 principal components. The analyses included all evaluable participants without stratification for race/ancestry. The two lowest P-value results are shown for each brain region. CNS, central nervous system. Linear regression analysis involved numbers of participants shown, for baseline plasma total bilirubin concentration. Analysis among all participants controlled for CYP2B6/CYP2A6 genotype level, age, and sex. Analysis among White, Black, and Hispanic participants controlled for the same covariates but did not control for principal components. The two lowest P-value results are shown for each population group.
sex, and two principal components, the lowest nominal P value was for rs7143465 in SLC8A3, which encodes solute carrier family 8 member A3 (P = 2.2 × 10 − 9 ). The two lowest nominal P-value polymorphisms among all participants and among White, Black, and Hispanic participants analyzed separately are presented in Table 6 .
For the four genes in Table 6 , we attempted to examine whether predicted expression in brain was associated with CNS events. Of these, CFAP36 was not represented in PrediXcan. Among White participants, but not among Black or Hispanic participants, predicted ACSF3 expression in brain tissues tended to be associated with grade 2 or greater CNS adverse events within 48 weeks, including in anterior cingulate cortex (P = 9.46 × 10 ). Of note, ACSF3 rs144103499 (Table 6) is not a known expression quantitative trait locus for ACSF3 in any tissue [42] . There were not associations with BBS12 or SLC8A3. The lowest P value for BBS12 was in cerebellum among Black participants (P = 0.092), and for SLC8A3 was in hypothalamus among all participants (P = 0.014).
Discussion
Among individuals who were randomly assigned to initial treatment with efavirenz-containing regimens in four ACTG studies, and with correction for multiple comparisons, we found no significant association between predicted expression of six neurotransmitter transporter and receptor genes postulated to mediate efavirenz effects in brain (SLC6A2, SLC6A3, PGR, HTR2A, HTR2B, HTR6) and grade 2 or greater CNS adverse events, both among all participants, and in analyses performed separately among White, Black, and Hispanic participants. The lowest nominal P value among all participants was for PGR in hippocampus (P = 0.012). Similarly, after correction for multiple comparisons we found no significant association between individuals SNPs in these genes or AR and HTR2C and grade 2 or greater CNS adverse events, both among all participants, and in analyses performed separately among White, Black, and Hispanic participants. The lowest nominal P value was for rs12393326 in HTR2C (P = 6.7 × 10
−4
).
Analyses were controlled for CYP2B6/CYP2A6 genotype, age, and sex, and, in analyses that pooled all race/ethnicity groups, also the first two principal components. We demonstrated significant, though weak, associations between CYP2B6/CYP2A6 genotype level and grade 2 or greater CNS adverse events, which is generally consistent with several previous reports [18, 23, 24] . It was therefore important that we adjust for CYP2B6/CYP2A6 genotype level in analyses for associations with predicted neurotransmitter transporter/receptor gene expression and polymorphisms. In addition, controlling for principal components in analyses involving all participants reduced Logistic regression analysis involved the indicated numbers of grade 2 or greater CNS event cases and efavirenz-tolerant controls. We considered polymorphisms in SLC6A2, SLC6A3, NR3C3, HTR2A, HTR2B, HTR2C, HTR6, and NR3C4 100 kB. The analysis controlled for CYP2B6/CYP2A6 genotype level, age, sex, and, for the analysis involving all participants, the first two principal components. The two lowest P-value results are shown for each race/ancestry group. CNS, central nervous system; MAF, minor allele frequency. By analyzing all participants pooled, as well as racial/ ethnic groups of White, Black, and Hispanic participants separately, we had the potential to identify consistent genetic associations across groups. Although true genetic associations need not be present in all populations, finding the same association in all participants and in each race/ethnicity group increases the likelihood that the association is not by chance. For example, associations between CYP2B6 genotype level and plasma efavirenz concentrations were previously shown in pooled analyses and among White, Black, and Hispanic participants analyzed separately [15] . In the present analyses, neither predicted gene expression levels or polymorphisms with the lowest P values were consistent across populations.
We cannot explain the apparent association between female sex and fewer grade 2 or greater CNS adverse events among all participants, and among White participants and Black participants analyzed separately. Previous reports have been inconsistent in this regard, with studies showing no difference by sex [43, 44] , increased efavirenz CNS adverse events in males [45] , and increased CNS adverse events in females [46] .
This study has limitations. Because providers may not have referred patients perceived to be at increased risk for CNS adverse events to studies of efavirenz, risk may be underestimated. Analyses largely involved White, Black, and Hispanic participants in the USA, so findings may not translate to other countries or race/ethnicity groups.
The open-label design of three of the four studies might have biased investigators into reporting CNS adverse events in patients randomized to efavirenz. Although PrediXcan readily identified an association between predicted UGT1A1 expression in liver and bilirubin concentrations, this does not prove that we could detect associations of efavirenz CNS adverse events with predicted gene expression levels in brain. To our knowledge, there is no brain gene-phenotype pair in our dataset that could serve as a positive control. A larger sample size would increase power to identify associations. The present study was not designed to address rare polymorphisms, epigenetics, inducibility of gene expression, and trans-regulatory elements. In addition, factors not evaluated in this study such as nicotine and alcohol use may affect expressions of CYP2B6, CYP2A6, and other genes, and could conceivably differ by ancestry.
Conclusion
It is important to identify genetic factors that affect susceptibility to antiretroviral toxicities. The present study suggests that interindividual differences in brain neurotransmitter transporter/receptor genomics may not explain variable susceptibility to efavirenz CNS adverse events.
